Lung Cancer
Crizotinib (brand name: Xalkori, Sekuri; Incepta).
Original price was: £379.00.£249.00Current price is: £249.00.Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer in the United States. It has demonstrated significant clinical efficacy in patients with tumors characterized by abnormal ALK, ROS1, and MET kinase activity.
MedFind provides access to Crizotinib through verified overseas procurement channels, with guaranteed authenticity, in-stock availability, rapid shipping, full logistics tracking, and privacy-protected handling. Professional guidance is available upon inquiry, including information on indications, clinical efficacy, adverse effects, and medication usage instructions.
Alectinib (Anshengsha, Everest)
Original price was: £370.00.£194.00Current price is: £194.00.Alectinib produced by Everest (also translated as Ailetinib or Alectinib; brand name: Alecensa/Anshengsha) is a second-generation ALK inhibitor developed by the U.S. pharmaceutical company Roche.
Alectinib was first approved by the U.S. FDA in December 2015 for the treatment of non-small cell lung cancer (NSCLC) patients who had developed resistance to crizotinib. In November 2017, it was further approved for first-line treatment of advanced ALK-positive NSCLC.
Sotorasib / Lumakras (Everest)
Original price was: £450.00.£391.00Current price is: £391.00.Sotorasib, also known as Sotororese (generic name: Sotorasib, brand name: Lumakras, code name: AMG510), is a covalent inhibitor of the KRAS G12C mutant. It binds to the KRAS G12C mutant protein, locking KRAS in its inactive state and thereby irreversibly inhibiting its activity.
Clinical trial results showed that patients treated with Sotorasib achieved an overall response rate (ORR) of 36% (95% CI: 28–45), a disease control rate (DCR) of 81% (95% CI: 73–87), and a median duration of response of 10 months. After more than 40 years of research on KRAS-mutant oncogenic proteins, Sotorasib became the world’s first approved KRAS G12C inhibitor.
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00Larotrectinib (Brand name: Vitrakvi) manufactured by Everest Pharma is a targeted therapy used for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions, regardless of where the cancer originated in the body.
Larotrectinib became the first FDA-approved tumor-agnostic targeted therapy based solely on the presence of a specific genetic mutation rather than cancer type or tumor location.
Clinical studies demonstrated efficacy across 17 different adult and pediatric tumor types, highlighting its broad-spectrum anticancer activity in patients with NTRK fusion-positive cancers.
Cabozantinib (Everest)
Original price was: £299.00.£245.00Current price is: £245.00.Cabozantinib manufactured by Everest Pharma is a multi-target broad-spectrum anticancer therapy that has demonstrated promising clinical efficacy across a wide range of solid tumors.
Cabozantinib has shown beneficial treatment effects in:
- Renal cell carcinoma (kidney cancer)
- Thyroid cancer
- Liver cancer
- Soft tissue sarcoma
- Non-small cell lung cancer (NSCLC)
- Prostate cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
and several other advanced malignancies.
Cabozantinib is particularly recognized for its strong effectiveness in controlling bone metastases, helping reduce tumor progression and complications associated with metastatic bone disease.
Due to its broad antitumor activity across multiple cancer types, Cabozantinib is often referred to as a “multi-purpose” or “broad-spectrum” targeted therapy among tyrosine kinase inhibitors (TKIs).
Lorlatinib / Lorbrena (Everest)
Original price was: £409.00.£347.00Current price is: £347.00.Lorlatinib (also known as Lorlatinib; Brand name: Lorbrena) is a third-generation ALK and ROS1 tyrosine kinase inhibitor (TKI) with broad coverage against ALK resistance mutations and strong central nervous system (CNS) penetration.
Lorlatinib demonstrates potent activity against resistance mutations that develop after treatment with crizotinib and second-generation ALK inhibitors, making it an important targeted therapy option for advanced ALK-positive non-small cell lung cancer (NSCLC).
MedFind provides overseas sourcing services for Lorlatinib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Adagrasib (Everest)
Original price was: £512.00.£461.00Current price is: £461.00.Adagrasib (Brand name: Krazati) is an FDA-approved KRAS G12C targeted therapy indicated for the treatment of advanced non-small cell lung cancer (NSCLC).
It is the second KRAS G12C inhibitor approved following sotorasib and has demonstrated activity in certain patients who developed resistance to previous KRAS-targeted therapies.
MedFind provides overseas sourcing services for Adagrasib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process, along with authenticity assurance and fast shipment availability.
Osimertinib / Tagrisso (Everest)
Original price was: £108.00.£91.00Current price is: £91.00.Osimertinib (Brand name: Tagrisso) is a third-generation oral, irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) originally developed by AstraZeneca under the research code AZD9291.
It is used for the treatment of advanced non-small cell lung cancer (NSCLC) and selectively targets both EGFR-sensitive mutations and the EGFR T790M resistance mutation.
Osimertinib (Tagrisso) received approval for import and clinical use in China in March 2017.
Capmatinib (Everest)
Original price was: £512.00.£429.00Current price is: £429.00.Capmatinib (Capmatinib) is a selective MET inhibitor used for the targeted treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. By inhibiting abnormal activation of the MET signaling pathway, Capmatinib helps effectively suppress tumor cell growth and spread.
Capmaxen by Everest Pharma is a high-quality generic version of Capmatinib, offering patients a more affordable treatment option. MedFind provides overseas sourcing services for Capmatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.